[Form 4] Vor Biopharma Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) Form 4: Reprogrammed Interchange LLC and Reid Hoffman reported a series of open-market sales of common stock in early September 2025. Reprogrammed sold 554,612 shares on 09/03/2025 at a weighted average price of $1.9961, 453,016 shares on 09/04/2025 at $1.9285, and 400,000 shares on 09/05/2025 at $1.9682. Following these transactions, Reprogrammed's reported beneficial ownership decreased from 36,329,955 shares to 35,476,939 shares. The filing notes that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed but disclaims ownership except for pecuniary interest.

Positive

• Timely and complete disclosure of multiple sales across three days with explanatory footnotes
• Weighted average prices and price ranges are provided with offer to supply transaction-level detail on request

Negative

• Significant insider disposals: total of 1,407,628 shares sold across three days
• Reported beneficial ownership declined from 36,329,955 to 35,476,939 shares for Reprogrammed Interchange LLC

Insights

Financial Analyst

TL;DR: Significant insider sales totaling 1,407,628 shares were reported over three days, reducing reported beneficial holdings modestly.

The filing documents three separate open-market dispositions executed on 09/03/2025, 09/04/2025 and 09/05/2025 with reported weighted average sale prices. Aggregate share count sold (1,407,628) is explicit in the form lines. For investors, these are material disclosures of insider liquidity but the form does not state proceeds, intent, or use of proceeds. Compliance with Section 16 reporting is satisfied by the Form 4 signatures from both Reprogrammed's manager and Reid Hoffman.

Corporate Governance Expert

TL;DR: The filing shows routine Section 16 reporting for multiple sales by an entity controlled by a director; ownership disclaimers are included.

The filing correctly identifies Reprogrammed Interchange LLC as the direct holder and explains Reid Hoffman’s potential indirect beneficial status while disclaiming ownership beyond pecuniary interest. The explanatory footnotes provide weighted average price ranges and offer to produce transaction-level detail to the SEC or issuer, which aligns with disclosure best practices. The filing does not disclose any Rule 10b5-1 plan or other contractual sale arrangement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S		554,612	D	$1.9961(1)	36,329,955(2)	D
Common Stock	09/04/2025		S		453,016	D	$1.9285(3)	35,876,939(2)	D
Common Stock	09/05/2025		S		400,000	D	$1.9682(4)	35,476,939(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Hoffman Reid

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.99 to $2.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

3. This transaction was executed in multiple trades at prices ranging from $1.91 to $2.005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $1.935 to $1.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Frank Huang, Manager of Reprogrammed Interchange LLC	09/05/2025
	/s/ Reid Hoffman	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Vor Biopharma (VOR) shares were sold in this Form 4?

1,407,628 shares were sold in aggregate: 554,612 on 09/03/2025, 453,016 on 09/04/2025, and 400,000 on 09/05/2025.

What weighted average prices were reported for the VOR sales?

$1.9961 on 09/03/2025, $1.9285 on 09/04/2025, and $1.9682 on 09/05/2025; the filing notes trades executed over stated price ranges.

Who is the direct reporting entity and what is Reid Hoffman’s relationship to the shares?

Reprogrammed Interchange LLC is the direct holder; Reid Hoffman may be deemed an indirect beneficial owner due to shared control but disclaims ownership except for pecuniary interest.

Did the Form 4 indicate a 10b5-1 trading plan or deemed execution date?

No 10b5-1 plan is indicated and no deemed execution dates are reported for these transactions.

What is the reported beneficial ownership after the transactions?

35,476,939 shares are reported as beneficially owned by Reprogrammed Interchange LLC following the sales.